Thermo Fisher Scientific Inc. $TMO Stock Sold by Professional Advisory Services Inc.

09 Oct 2026, 00:07 by Michael Walen · The Markets Daily

Professional Advisory Services Inc. reduced its stake in Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 21.9% in the 3rd quarter, Holdings Channel reports. The firm owned 50,612 shares of the medical research company’s stock after selling 14,207 shares during the quarter. Thermo Fisher Scientific accounts for approximately 4.0% of Professional Advisory Services Inc.’s portfolio, making the stock its 5th biggest position. Professional Advisory Services Inc.’s holdings in Thermo Fisher Scientific were worth $34,166,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Davis Capital Management increased its stake in Thermo Fisher Scientific by 122.3% during the 3rd quarter. Davis Capital Management now owns 1,356 shares of the medical research company’s stock worth $915,000 after buying an additional 746 shares during the period. Farther Finance Advisors LLC increased its position in shares of Thermo Fisher Scientific by 13.2% during the third quarter. Farther Finance Advisors LLC now owns 14,829 shares of the medical research company’s stock worth $10,010,000 after acquiring an additional 1,731 shares during the last quarter. Brighton Securities CORP. purchased a new position in Thermo Fisher Scientific in the third quarter valued at about $249,000. Atwood & Palmer Inc. grew its stake in Thermo Fisher Scientific by 6.7% during the 3rd quarter. Atwood & Palmer Inc. now owns 58,434 shares of the medical research company’s stock valued at $39,446,000 after purchasing an additional 3,688 shares in the last quarter. Finally, Fenimore Asset Management Inc increased its stake in shares of Thermo Fisher Scientific by 781.0% in the third quarter. Fenimore Asset Management Inc now owns 53,830 shares of the medical research company’s stock worth $36,338,000 after buying an additional 47,720 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific News Summary

Here are the key news stories impacting Thermo Fisher Scientific this week:

Positive Sentiment: Thermo Fisher helped launch the Digital CMC Consortium, bringing biopharma companies, technology providers and regulators together to establish digital standards for chemistry, manufacturing and controls data. The initiative could support faster drug development, more efficient regulatory reviews and recurring digital lifecycle-management opportunities. What Could Thermo Fisher Scientific Change With Its New Digital CMC Consortium?
Positive Sentiment: Thermo Fisher’s clinical research business signed an agreement with Quantum BioPharma to support a Phase 2 multiple sclerosis trial for Lucid-MS. The contract reinforces demand for the company’s contract research services, although the near-term financial impact was not disclosed. Quantum BioPharma Enlists Thermo Fisher’s Clinical Research Business
Neutral Sentiment: Industry reports project strong long-term growth in pharmaceutical contract research, PCR testing and cell-based assay markets, where Thermo Fisher is a major participant. These reports improve the sector’s growth backdrop but do not represent new company guidance or orders. Pharmaceutical CRO Market Forecasts Growth PCR Market Report Forecasts Growth
Negative Sentiment: Profit-taking is likely after a strong rally supported by Thermo Fisher’s prior earnings beat. With the next results approaching, investors may be waiting for confirmation that biopharma and laboratory spending remain strong enough to justify the stock’s elevated valuation.
Negative Sentiment: Quiver Quantitative reported that insiders made no open-market purchases and recorded 94 sales over the past six months, including substantial sales by senior executives. Recent analyst price targets cited in the report were generally below the prevailing share price, which may reinforce valuation concerns. The data should be interpreted cautiously because insider sales can reflect compensation and diversification.

Thermo Fisher Scientific Stock Performance

NYSE:TMO traded down $10.43 during mid-day trading on Thursday, hitting $651.63. The stock had a trading volume of 2,585,462 shares, compared to its average volume of 2,253,558. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. The company has a 50 day simple moving average of $625.73 and a 200-day simple moving average of $540.54. The stock has a market capitalization of $240.94 billion, a price-to-earnings ratio of 35.05, a P/E/G ratio of 2.75 and a beta of 0.87. Thermo Fisher Scientific Inc. has a 52 week low of $435.27 and a 52 week high of $694.33.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The company had revenue of $11.99 billion for the quarter, compared to analysts’ expectations of $11.71 billion. During the same quarter in the previous year, the company posted $4.28 earnings per share. The business’s revenue for the quarter was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, research analysts expect that Thermo Fisher Scientific Inc. will post 25.13 earnings per share for the current fiscal year.

Analyst Ratings Changes

TMO has been the topic of a number of research analyst reports. Morgan Stanley increased their target price on Thermo Fisher Scientific from $620.00 to $650.00 and gave the stock an “overweight” rating in a report on Friday, July 24th. Royal Bank Of Canada increased their target price on shares of Thermo Fisher Scientific from $490.00 to $580.00 and gave the stock a “sector perform” rating in a report on Friday, July 24th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $630.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, July 23rd. CLSA assumed coverage on shares of Thermo Fisher Scientific in a research note on Thursday, September 3rd. They set an “outperform” rating and a C$748.00 price objective on the stock. Finally, Evercore set a $570.00 target price on Thermo Fisher Scientific in a research note on Monday, July 6th. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, four have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and an average target price of $635.55.

Read Our Latest Stock Analysis on Thermo Fisher Scientific

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Michael D. Shafer sold 25,500 shares of the business’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the sale, the executive vice president directly owned 20,994 shares in the company, valued at approximately $12,596,400. The trade was a 54.85% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 275 shares of the stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $627.05, for a total transaction of $172,438.75. Following the completion of the transaction, the chief executive officer owned 123,925 shares of the company’s stock, valued at $77,707,171.25. This trade represents a 0.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 73,768 shares of company stock valued at $44,122,820 in the last ninety days. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Profile

(Free Report)

Thermo Fisher Scientific Inc is a global provider of laboratory products, analytical instruments, reagents, consumables, software and services. Its offerings support research, drug discovery and development, clinical diagnostics, biotechnology and pharmaceutical manufacturing, as well as environmental, industrial and other applied markets.